Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Phase 1/2 Modular Dose Escalation With Cohort Expansion of CP-506 (HAP) in Patients With Solid Tumor Types With High Incidence of HRD/FAD in Monotherapy or With Carboplatin or Patients With Solid Tumour and OPD Receiving ICI
Sponsor: Academisch Ziekenhuis Maastricht
This PHASE1/PHASE2 trial investigates Unspecified Adult Solid Tumor, Protocol Specific and is currently actively recruiting participants. Academisch Ziekenhuis Maastricht leads this study, which shows 10 recorded versions since 2023 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Nov 2025 — Present [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2024 — Nov 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2023 — May 2024 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 5 earlier versions
-
Jun 2023 — Oct 2023 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2023 — Jun 2023 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Jul 2022 — Apr 2023 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Jun 2022 — Jul 2022 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Sep 2021 — Jun 2022 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Academisch Ziekenhuis Maastricht
- Erasmus Medical Center
- Jules Bordet Institute
- Maastricht University Medical Center
- University Ghent
- Vall d'Hebron Institute of Oncology
For direct contact, visit the study record on ClinicalTrials.gov .